Equilab International expanded its business to Central Laboratory testing services and held an inauguration ceremony on February 5, 2024. This Central Laboratory facility was inaugurated by the Acting Head of the National Agency of Drug and Food Control (BPOM), Dr. Dra. Lucia Rizka Andalucia, Apt, M.Pharm, MARS. The ceremony was also attended by Dra. Rita Endang, Apt., M.Kes as the Acting Deputy for Supervision of Drugs, Narcotics, Psychotropics, Precursors, and Addictive Substances BPOM, Mohamad Kashuri, S.Si, Apt, M.Farm as the Deputy for Traditional Medicines, Health Supplements, and Cosmetics Supervision BPOM, other BPOM officials and invited guests graced the occasion.
A Central Laboratory plays a crucial role in fulfilling drug testing requirements and also during the drug development process. It should be standardized to meet the regulatory requirements. I hope it can help to provide high-quality drugs and also anticipate drug shortages in Indonesia. Equilab should expand continuously”, Dr. Rizka explained.
Director of Equilab International, Mr. Wimala Widjaja explained that this new dedicated Central Laboratory facility is an expansion of Equilab’s existing building. This facility is expected to answer customer needs and regulatory requirements with high-quality result and meet the customer’s timeline.
“As the first Contract Research Organization (CRO) in Indonesia and the largest CRO in Southeast Asia, Equilab commits to driving innovation both in our research efforts and in expanding our business venture, leveraging our analytical and clinical strengths to run impactful studies in Indonesia. Our testing results have been accepted in many countries, not only in Asia, but also in many countries in Europe and Africa,” said Mr. Ronal Simanjuntak, General Manager of Equilab International.